Welcome to our dedicated page for Harrow Health SEC filings (Ticker: HROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ophthalmic drug approvals, compounding economics, and FDA milestones make Harrow Health’s disclosures dense reading. If you have ever searched for “Harrow Health SEC filings explained simply” or wished for a “Harrow Health annual report 10-K simplified,” you know how quickly technical jargon slows real analysis. Stock Titan’s AI-driven platform opens every Harrow filing with context, highlighting how its Dextenza distribution agreements, in-office sedation products, and research expenses shape long-term value.
Need the numbers fast? Our tool streams each “Harrow Health quarterly earnings report 10-Q filing” the moment it hits EDGAR, then produces a concise “Harrow Health earnings report filing analysis” that isolates revenue per ophthalmic segment, compounding margins, and cash runway. It also decodes Form 8-K notices—think “Harrow Health 8-K material events explained”—so you instantly see how licensing deals or FDA complete response letters may move the stock. In short, you’re “understanding Harrow Health SEC documents with AI,” not digging through footnotes.
Monitoring management behavior is just as effortless. Receive alerts for “Harrow Health insider trading Form 4 transactions,” review “Harrow Health Form 4 insider transactions real-time,” and compare option grants under the “Harrow Health executive stock transactions Form 4” label. Preparing for the annual meeting? Our AI highlights board pay metrics inside every “Harrow Health proxy statement executive compensation” section. From 10-K to 8-K, Stock Titan delivers complete coverage, real-time updates, and expert clarity—so you spend time acting on insights, not hunting for them.
Harrow Director Perry J. Sternberg received a grant of 7,339 Restricted Stock Units (RSUs) on June 20, 2025, as reported in this Form 4 filing. The RSUs were awarded as compensation for services rendered or to be rendered.
Key terms of the RSU grant:
- Conversion price: $0
- Vesting schedule: Full vesting on the one-year anniversary of the grant date
- Transfer restrictions: Underlying shares cannot be delivered, transferred, or sold until termination of service
- Ownership form: Direct
The transaction was reported by Andrew R. Boll as Attorney in Fact for Perry J. Sternberg on June 24, 2025. This equity grant aligns with common director compensation practices and creates additional alignment between the director's interests and those of shareholders.
Harrow Director Lauren P. Silvernail received a grant of 7,339 Restricted Stock Units (RSUs) on June 20, 2025, as reported in this Form 4 filing. The RSUs were awarded as compensation for services rendered or to be rendered.
Key terms of the RSU grant:
- Conversion price: $0
- Vesting schedule: Full vesting occurs on the one-year anniversary of the grant date
- Transfer restrictions: Underlying shares cannot be delivered, transferred, or sold until termination of service
- Ownership form: Direct
This transaction represents a standard director compensation arrangement, with the RSUs serving as long-term incentive compensation aligned with shareholder interests. The filing was signed by Andrew R. Boll as Attorney in Fact for Lauren P. Silvernail on June 24, 2025.
Director Adrienne L. Graves of Harrow received a new equity compensation award on June 20, 2025, as reported in this Form 4 filing. The transaction details include:
- Awarded 7,339 Restricted Stock Units (RSUs) with $0 exercise price
- RSUs will vest fully on the one-year anniversary of the grant date
- Underlying shares cannot be delivered, transferred, or sold until termination of service
This grant appears to be part of the company's director compensation program, representing a standard compensatory award for board service. The filing was submitted by Andrew R. Boll as Attorney in Fact for the director on June 24, 2025, within the required reporting window. Ms. Graves holds these RSUs under direct ownership.
Harrow has filed a Form S-8 registration statement to register securities under its new 2025 Incentive Stock and Awards Plan. The company, an accelerated filer based in Nashville, Tennessee, is registering shares for employee benefit purposes.
Key aspects of the filing include:
- Registration covers the newly adopted 2025 Incentive Stock and Awards Plan
- Filing incorporates by reference the Annual Report for 2024, Q1 2025 Quarterly Report, and recent Current Reports
- Company maintains comprehensive indemnification provisions for directors and officers under Delaware law
- Legal opinion provided by Holland & Knight LLP regarding share legality
- Independent accounting firms Crowe LLP and KMJ Corbin & Company LLP provided consents
The filing includes standard undertakings regarding post-effective amendments and removal of unsold securities. Mark L. Baum, CEO, and Andrew R. Boll have been granted power of attorney for filing amendments.
Key Takeaway: Harrow Inc.’s 2025 Annual Meeting (18-Jun-2025) produced broad shareholder support on every agenda item, reaffirming governance stability without introducing immediate balance-sheet or earnings effects.
A strong quorum of 31.27 million shares (85.2 % of the 36.69 million entitled) was present. All four director nominees—Mark L. Baum, Adrienne L. Graves, Lauren P. Silvernail and Perry J. Sternberg—were re-elected with at least 98.8 % of votes cast, signalling investor confidence in existing leadership.
The new 2025 Incentive Stock and Awards Plan passed with 21.70 million ‘For’ (90.5 % of votes cast, excl. broker non-votes) versus 1.77 million ‘Against’. The plan gives the board fresh equity-compensation capacity, potentially increasing future dilution if fully utilised.
Audit matters were routine: shareholders ratified Crowe LLP for FY-2025 with 31.23 million ‘For’ (99.8 %), removing audit-continuity uncertainty. Advisory votes showed 94.1 % support for executive pay and 82.5 % support for holding a say-on-pay vote every year.
No M&A, financing, or earnings guidance was disclosed. Overall, this 8-K reflects standard corporate-governance maintenance rather than a catalyst for near-term valuation change.
FAQ
What is the current stock price of Harrow Health (HROW)?
What is the market cap of Harrow Health (HROW)?
What is Harrow Health Inc's primary focus?
What types of products does the company offer?
How does Harrow Health Inc generate revenue?
What differentiates Harrow Health from its competitors?
In which market does Harrow Health primarily operate?
What role does research and development play in the company?
How does the company support clinical practices?
Can you explain the company’s approach to quality assurance?
